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Objectives We sought to compare the efficacy and safety of dronedarone versus amiodarone for the prevention of recurrent
atrial fibrillation (AF).
Background Dronedarone is a noniodinated amiodarone congener developed to maintain sinus rhythm. Few data are avail-
able to directly compare the efficacy and safety of dronedarone versus amiodarone.
Methods We conducted a systematic overview of all randomized controlled trials in which the authors evaluated dronedar-
one or amiodarone for the prevention of AF. The effect of amiodarone versus dronedarone was summarized by
the use of indirect comparison meta-analysis and normal logistic meta-regression models.
Results We identified 4 placebo-controlled trials of dronedarone, 4 placebo-controlled trials of amiodarone, and 1 trial of
dronedarone versus amiodarone. By using random-effects modeling, we found that there was a significant esti-
mated reduction in recurrent AF with amiodarone versus placebo (odds ratio [OR]: 0.12; 95% confidence interval
[CI]: 0.08 to 0.19) but not dronedarone versus placebo (OR: 0.79; 95% CI: 0.33 to 1.87). A normal logistic re-
gression model incorporating all trial evidence found amiodarone superior to dronedarone (OR: 0.49; 95% CI:
0.37 to 0.63; p  0.001) for the prevention of recurrent AF. In contrast, these models also found a trend toward
greater all-cause mortality (OR: 1.61; 95% CI: 0.97 to 2.68; p  0.066) and greater overall adverse events re-
quiring drug discontinuation with amiodarone versus dronedarone (OR: 1.81; 95% CI: 1.33 to 2.46; p  0.001).
Conclusions Dronedarone is less effective than amiodarone for the maintenance of sinus rhythm, but has fewer adverse ef-
fects. For every 1,000 patients treated with dronedarone instead of amiodarone, we estimate approximately
228 more recurrences of AF in exchange for 9.6 fewer deaths and 62 fewer adverse events requiring discontinu-
ation of drug. (J Am Coll Cardiol 2009;54:1089–95) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.085o
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mtrial fibrillation (AF) is the most common sustained
ardiac arrhythmia. Affecting more than 2.5 million people
n the U.S., AF is a major burden to the public health and
he health care system (1). Many patients require a rhythm-
anagement strategy designed to maintain sinus rhythm,
revent recurrent AF, and improve quality of life. Rhythm
anagement is hindered by the impotence of current
ntiarrhythmic drugs and mounting safety concerns, includ-
ng increased rates of mortality (2–5).
Amiodarone is presently the most effective antiarrhyth-
ic agent for AF, but its use is limited by toxicity (6–8).
ronedarone is a noniodinated benzofuran similar to ami-
ontinuing Medical Education (CME) is available for this article. From the Division
f Cardiology, Duke Clinical Research Institute, Duke University Medical Center,
urham, North Carolina. Dr. Piccini is supported by an American College of
ardiology Foundation/Merck Award.a
Manuscript received March 13, 2009; revised manuscript received April 22, 2009,
ccepted April 28, 2009.darone but is not associated with thyroid or pulmonary
oxicity. Dronedarone has electrophysiological characteris-
ics spanning all 4 Vaughan-Williams antiarrhythmic
lasses, with primarily Class III effects. Initial small trials
uggested that dronedarone prolonged the time to recur-
ence of AF and reduced cardiovascular death and hospital-
zation (9,10). However, the long-term maintenance of
inus rhythm at 12 months was less encouraging (10).
See page 1096
The clinical decision to prescribe drugs for rhythm
anagement hinges on estimates of their net clinical benefit
11). Few direct comparisons of dronedarone and amioda-
one exist, although each drug has been evaluated exten-
ively against placebo. Under these circumstances, we con-
ucted a systematic overview using indirect comparison
eta-analysis and normal logistic models to summarize the
vailable evidence (12–14).
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Dronedarone and Amiodarone September 15, 2009:1089–95Methods
Study search. We searched
MEDLINE (1966 to 2009) and
the National Institutes of Health’s
ClinicalTrials.gov database for
published and unpublished ran-
domized controlled trials of drone-
arone versus placebo, amiodarone versus placebo, and drone-
arone versus amiodarone for the prevention of recurrent AF.
e searchedMEDLINE using the following medical subject
eading terms: 1) dronedarone, placebo, atrial fibrillation,
nd randomized controlled trials; and 2) amiodarone, pla-
ebo, atrial fibrillation, and randomized controlled trials. A
hird MEDLINE search string (amiodarone, dronedarone,
trial fibrillation, and randomized controlled trials) revealed
o additional citations. MEDLINE queries were limited to
tudies involving human subjects that were written in
nglish. Finally, the bibliographies of 3 narrative and
ystematic reviews were manually searched for additional
itations (3,8,15).
Abbreviations
and Acronyms
AF  atrial fibrillation
CI  confidence interval
OR  odds ratio
Figure 1 Study Selection Process
Shown here is the study selection process according to the Quality of Reporting of
yielded 4 trials of dronedarone versus placebo, 4 trials of amiodarone versus placligibility and data abstraction. Controlled studies that
andomized patients with AF to amiodarone, dronedarone,
r placebo were included in the analysis. Additional selec-
ion criteria included treatment with follow-up for 6
onths and availability of recurrent AF or all-cause mor-
ality as end points. Studies of subjects age 18 years and
ubjects with acute cardioversion, catheter ablation, and
ost-operative AF were excluded.
We reviewed citations and abstracted data in a standard-
zed and unblinded fashion. Data were abstracted from each
eport, including inclusion and exclusion criteria, demo-
raphics, baseline characteristics, trial design (including the
reatment and control arms), study quality, follow-up, and
tudy outcomes. Pre-specified outcomes included the fol-
owing: 1) recurrence of AF; 2) all-cause mortality; and
) adverse events that required study drug cessation. All
utcomes were analyzed according to intention to treat.
igure 1 depicts the study selection process (16).
tatistical analysis. Odds ratios (ORs) summarizing the
ffectiveness of each drug compared with placebo were
alculated with the use of Fast*Pro software (17). We
-analyses guidelines. The systematic search
nd 1 direct head-to-head comparison of amiodarone and dronedarone.Meta
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September 15, 2009:1089–95 Dronedarone and Amiodaroneombined these ORs by assuming an empirical Bayesian
odel described by Hedges and Olkin (18). Risk differences
etween control and treatment arms also were combined by
he use of the same model. The empirical Bayesian random-
ffects model reduces to a fixed-effects model when the
tudies are homogeneous. The method accommodated het-
rogeneity by assuming that the true effect differed among
tudies and therefore must be represented by a distribution
f values instead of a single value. The result was a wider
ange of uncertainty about the point estimate than was
alculated with fixed-effects models.
To estimate a comparison between amiodarone and
ronedarone from these data, we calculated the following
roduct:
Odds of event on amiodarone
Odds of event on dronedarone

Odds of event on amiodarone
Odds of event on placebo ⁄Odds of event on dronedaroneOdds of event on placebo
his fundamental relationship has been previously exam-
ned by several investigators (12,14,19). To further examine
he relationship between amiodarone and dronedarone, we
sed the methods of Hasselblad (20) to fit a generalized
eta-analysis (meta-regression), using random-effects lo-
istic regression models with terms for each antiarrhythmic
rug and for each study.
The multivariate logistic normal models, implemented in
GRET software (Cytel Software Corp., Cambridge, Mas-
achusetts), contained a term for a random-error component
hat allowed for extra variation in the model. The models
ssume that the odds ratios between the various treatments
emain constant, except for some random variation.
esults
earch results. After searching the MEDLINE and Clini-
alTrials.gov databases, we identified 10 reports in the
ronedarone search and 88 reports in the amiodarone search
hat were reviewed for inclusion and exclusion criteria (Fig.
). Among this group of reports, 5 dronedarone studies and
3 amiodarone studies were excluded. The majority of
eports were excluded on the basis of the absence of
andomization (observational studies), because they were
tudies of acute cardioversion, or because they were studies
f post-operative AF (Fig. 1). The full papers for the
emaining 8 published trials were retrieved for detailed
eview and abstraction. The results of the DIONYSOS
Efficacy & Safety of Dronedarone Versus Amiodarone for
he Maintenance of Sinus Rhythm in Patients With Atrial
ibrillation) study (NCT00489736), which randomized
atients to either dronedarone or amiodarone, were publicly
eleased by the sponsor (Sanofi-Aventis, Bridgewater, New
ersey) (21).
rial characteristics and study quality. Four randomized
ontrolled trials of dronedarone were included in this weta-analysis (Table 1) (9,10,22). These 4 multicenter trials
nrolled 5,967 patients who were randomized to long-term
ronedarone or placebo. One study was a dose-ranging
tudy; the remaining trials used a common 800-mg daily
ose of dronedarone with a mean follow-up of 13  6
onths. The 4 randomized, placebo-controlled trials of
miodarone enrolled a total of 669 patients (7,23–25). All of
he amiodarone trials used a daily maintenance dose of 200
g. The mean follow-up duration was 16  5 months.
In all 4 dronedarone trials, patients with permanent AF
ere excluded. Additional exclusion criteria included ad-
anced symptomatic heart failure, a corrected QT interval
500 ms, and bradycardia with a heart rate 50 beats/min
Table 1). In contrast to the dronedarone trials, the amio-
arone trials predominantly included patients with persis-
ent and permanent AF. Two amiodarone trials (GEFACA
Grupo de Estudio de Fibrilacion Auricular Con Amioda-
ona] and SAFE-T [Sotalol Amiodarone Atrial Fibrillation
fficacy Trial]) excluded patients with paroxysmal AF
7,24). Using the Delphi criteria (26), we determined that 7
f the 8 trials were of high quality, with a score of 6 or
reater (Table 1). One trial was single-blind and had a score
f 5 (25). Among the 8 trials, 2 did not report power
alculations (24,25).
aseline patient characteristics. Baseline patient charac-
eristics for each trial are shown in Table 2. The mean age
cross all 8 trials was 65  3 years. Seventy percent of those
nrolled were men. The SAFE-T trial, the largest published
andomized trial of amiodarone, conducted in the Veterans
dministration, enrolled an almost entirely male population
7). The mean left atrial diameter overall was 44  2 mm,
nd the mean left ventricular ejection fraction in all trials
xceeded 50%. All trials followed patients at least 6 months
range 6 to 22 months). In the 3 dronedarone trials that
eported concomitant pharmacotherapy, beta-blocker use
anged from 52% to 71% (9,10,24,25).
fficacy of dronedarone versus placebo. For prevention of
F 6 months (Fig. 2A), the effect of dronedarone had an
R of 0.79 (95% confidence interval [CI]: 0.33 to 1.87),
ith a risk difference of 0.040 (95% CI: 0.19 to 0.11)
quivalent to 40 fewer events per 1,000 patients treated. For
ortality, the OR was 0.85 (95% CI: 0.66 to 1.11), with a
isk difference of 0.003 (95% CI: 0.011 to 0.006). For
dverse events requiring discontinuation, there was a signif-
cant increase over placebo with OR: 1.166 (95% CI: 1.36 to
.02) and risk difference 0.045 (95% CI: 0.028 to 0.062).
fficacy of amiodarone versus placebo. Compared with
lacebo, amiodarone significantly prevented AF in
ollow-up (Fig. 2A), with an OR of 0.12 (95% CI: 0.08 to
.19) and a risk difference of 0.401 (95% CI: 0.46 to
0.34) equivalent to 401 fewer events per 1,000 patients
reated. For mortality, the OR was 1.88 (95% CI: 0.54 to
.56), with a risk difference of 0.005 (95% CI: 0.016 to
.026). For adverse events requiring discontinuation, there
as a significant increase over placebo with an OR of 11.04
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Dronedarone and Amiodarone September 15, 2009:1089–9595% CI: 1.89 to 64.5) and risk difference of 0.128 (95% CI:
.023 to 0.230).
omparative efficacy of dronedarone and amiodarone.
he indirect meta-analysis estimates indicated that amio-
arone significantly reduced recurrent AF compared with
ronedarone (OR: 0.16; 95% CI: 0.06 to 0.42), with a risk
andomized Trials of Dronedarone or Amiodarone Versus PlaceboTable 1 Randomized Trials of Dronedarone or Amiodarone Vers
Trial (Ref. #) Year
No. of
Patients Inclusion Criteria
Dronedarone versus placebo
DAFNE (22) 2003 142† Persistent AF
Ages 2185 yrs
EURIDIS (10) 2007 612 AF episode within previous
3 months
Age 21 yrs
ADONIS (10) 2007 625 AF episode within previous
3 months
Age 21 yrs
ATHENA (9) 2009 4,628 Paroxysmal or persistent AF
Age 70 or 70 yrs with addit
risk factor for stroke
Amiodarone versus placebo
Kochiadakis et al. (25) 2000 125‡ Symptomatic paroxysmal or chron
Age 18 yrs
GEFACA (24) 2001 50§ Chronic AF
Channer et al. (23) 2004 99§ AF 72 h
Age 18 yrs
SAFE-T (7) 2005 390 AF 72 h
Number of Delphi criteria met of a total of 9. †DAFNE (Dronedarone Atrial FibrillatioN study after
ere included in this analysis. ‡Excluded 61 patients randomized to sotalol. §Only long-term trea
ADONIS  American-Australian-African Trial With DronedarONe In AF or AFL Patients for the
ospitalization or Death in Patients With Atrial Fibrillation; Cr  creatine; CrCl  creatine clearanc
hythm; GEFACA  Grupo de Estudio de Fibrilacion Auricular Con Amiodarona; GFR  glomerular
ork Heart Association; PA  pulmonary artery; SAFE-T  Sotalol Amiodarone Atrial Fibrillation E
aseline Patient Characteristics in Randomized Trials of Dronedarond Amiod rone Versus Placebo for the Maintenance of Sinus RhytTable 2 Baseline Pa ient Characteristics in Randomized Trialsand Amiodarone Versus Placebo for the Maintenance o
Trial (Ref. #)
Mean
Age
(yrs)
Male
(%)
Paroxysmal
AF
(%)
Persistent
AF
(%)
Perm
A
(
DAFNE (22) 65 68 0 100
EURIDIS (10) 62 69 NR NR
ADONIS (10) 64 69 NR NR
ATHENA (9) 72 53 NR NR
Kochiadakis et al. (25) 63 52 66 0
GEFACA (24) 63 73 0 0 1
Channer et al. (23) 67 78 0 100 N
SAFE-T (7) 67 99 0 79CE  angiotensin-converting enzyme; EF  ejection fraction; NR  not reported; other abbreviations asifference of 0.36 (95% CI: 0.52 to 0.19), which is
quivalent to 360 fewer events per 1,000 patients treated
Fig. 2A). This finding was consistent with the direct results
rom DIONYSOS (OR: 0.44; 95% CI: 0.30 to 0.64), with a
isk difference of 0.186 (95% CI: 0.266 to 0.1028).
he normal logistic model also indicated greater efficacy for
acebo
Exclusion Criteria Blind
Mean Follow-Up
(Months)
Delphi
Criteria*
Permanent AF
NYHA functional class III to IV
QT 500 ms
LVEF 35%
Double-blind 6 8
Permanent AF
HR 50 beats/min
NYHA functional class III to IV
Cr 1.7 mg/dl
Double-blind 12 9
Permanent AF
HR 50 beats/min
NYHA functional class III to IV
Cr 1.7 mg/dl
Double-blind 12 9
Permanent AF
NYHA functional class IV
HR 50 beats/min
GFR 10 ml/min
Double-blind 21 8
Refractory heart failure
LVEF 40%
Recent CV surgery
Single-blind 22 5
Paroxysmal AF
Age 75 yrs
HR 50 beats/min
LA diameter 60 mm
Double-blind 16 7
LVEF 20%
PA pressure 40 mm Hg
Significant valvular disease
Double-blind 12 9
Paroxysmal AF
NYHA functional class III/IV
CrCl 60 ml/min
Intolerance to beta-blockers
Double-blind 12 (minimum) 8
e cardioversion) was a dose-ranging study. Only the placebo and dronedarone 800 mg daily arms
atients included. Excluded 261 patients randomized to sotalol.
ance of Sinus Rhythm; AF  atrial fibrillation; ATHENA  A Trial With Dronedarone to Prevent
DIS  EURopean Trial In AF or AFL Patients Receiving Dronedarone for the maIntenance of Sinus
n rate; HR  heart rate; LA  left atrium; LVEF  left ventricular ejection fraction; NYHA  New
Trial.
onedarone
us Rhythm
Mean LA
Diameter
(mm)
Mean
EF
(%)
Heart
Failure
(%)
Warfarin
(%)
Beta-Blockers
(%)
ACE
Inhibitors
(%)
45 56 19 NR NR NR
42 60 17 68 60 42
43 58 18 72 52 37
NR NR 21 60 71 70
44 55 NR NR NR NR
48 NR NR 100 NR NR
44 58 NR 100 NR NR
48 50 25 100 NR NRus Pl
ional
ic AF
Electiv
tment p
Mainten
e; EURInehmof Dr
f Sin
anent
F
%)
0
0
0
0
34
00
R
21in Table 1.
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September 15, 2009:1089–95 Dronedarone and Amiodaronehe prevention of AF with amiodarone over dronedarone
OR: 0.49; 95% CI: 0.37 to 0.63; p  0.001).
As shown in Figure 2B, there was a mortality trend favoring
ronedarone in the indirect meta-analysis (amiodarone vs.
ronedarone OR: 2.20; 95% CI: 0.61 to 7.88; risk difference:
.008; 95% CI:0.015 to 0.030). This finding was consistent
ith the DIONYSOS trial (OR: 2.44; 95% CI: 0.48 to 12.6),
isk difference 0.011 (95% CI: 0.010 to 0.033). A similar
rend was observed in the normal logistic regression model
OR: 1.61; 95% CI: 0.97 to 2.68; p  0.066).
omparative safety of dronedarone and amiodarone. For
dverse effects requiring interruption of therapy (Fig.
C), the indirect meta-analysis estimate favored drone-
arone; amiodarone was associated with an increased
dds of study drug termination (OR: 6.65; 95% CI: 1.13
o 39.3) with a risk difference of 0.083 (95% CI: 0.022
Figure 2 Treatment Effect Estimates for Amiodarone and Drone
The plots demonstrate odds ratios for (A) recurrent atrial fibrillation, (B) all-cause
events requiring drug discontinuation with event rates to the right of each panel. Ao 0.1866). The effect was similar in DIONYSOS (OR: t.24; 95% CI: 1.13 to 4.43) with a risk difference of 0.057
95% CI: 0.010 to 0.105). In normal logistic models that
ummarized the totality of the evidence, a similar rela-
ionship was observed (OR: 1.81; 95% CI: 1.33 to 2.46;
 0.001). Organ-specific adverse reactions in the
miodarone versus placebo and the dronedarone versus
lacebo trials are shown in Table 3. Overall, the inci-
ence of thyroid toxicity (4% vs. 3%), symptomatic
radyarrhythmias (2.8% vs. 1.1%), and hepatotoxicity
3.5% vs. 2.5%) leading to treatment discontinuation
ere comparable between dronedarone and placebo. Pa-
ients receiving dronedarone had a greater incidence of
mpaired creatinine clearance compared with placebo
4.0% vs. 1.1%). There were no cases of torsades de
ointes in any of the patients administered amiodarone or
n the DIONYSOS trial (21). There was a single case of
ne
, and (C) adverse
iodarone; D  dronedarone; P  placebo; other abbreviations as in Table 1.daro
death
 amorsades de pointes in a patient receiving dronedarone in
A
p
(
D
T
c
d
A
d
d
p
m
d
a
i
p
r
t
p
d
r
o
n
t
d
d
p
A
s
n
t
p
p
a
l
m
i
m
e
d
r
a
d
a
s
p
p
i
A
i
i
a
d
T
d
t
m
t
p
(
o
l
w
f
S
i
m
g
m
e
i
d
c
i
w
a
d
h
p
1094 Piccini et al. JACC Vol. 54, No. 12, 2009
Dronedarone and Amiodarone September 15, 2009:1089–95THENA (A Trial With Dronedarone to Prevent Hos-
italization or Death in Patients With Atrial Fibrillation)
9).
iscussion
here are 3 major findings in our analysis of randomized
ontrolled trials of dronedarone and amiodarone. First,
ronedarone is less effective for the prevention of recurrent
F compared with amiodarone. On the other hand, drone-
arone is associated with fewer adverse events requiring
iscontinuation of treatment. Finally, given the limited
ower of the available studies and the limitations inherent to
eta-analysis, it remains unclear whether treatment with
ronedarone confers a survival advantage versus other anti-
rrhythmic pharmacotherapy, including amiodarone.
Drugs for AF have limited antiarrhythmic efficacy. Even
n highly selected clinical trial patient populations, most
atients develop recurrent AF within 1 year despite antiar-
hythmic therapy (3,7). At the same time, AF pharmaco-
herapy is limited by toxicities that constantly threaten
atient safety and quality of life (2–4,27). Although amio-
arone is commonly prescribed for the maintenance of sinus
hythm, its use has been plagued by dose-dependent end-
rgan toxicities, including thyroid dysfunction and pulmo-
ary fibrosis. Dronedarone offers the potential for less
oxicity and a shorter half-life (15). In the ATHENA trial,
ronedarone therapy decreased hospitalization due to car-
iovascular events or death (9). However, the composite end
oint was driven principally by hospitalizations, and the
THENA trial did not capture recurrent AF events. In this
ystematic overview, dronedarone was associated with sig-
ificantly fewer adverse effects and treatment discontinua-
ions and a trend toward reduced all-cause mortality com-
ared with amiodarone.
The critical question for clinical practice is whether these
otential benefits justify a retreat from the moderate efficacy
fforded by amiodarone. Although dronedarone may pro-
ong the time to recurrent AF early on (10), long-term
aintenance of sinus rhythm appears disappointing. If the
ndirect meta-analysis results are given the same approxi-
ate weight as the DIONYSOS direct comparison, we
stimate that for every 1,000 patients treated with drone-
Organ-Specific Adverse Reactions Requiring StuTable 3 Organ-Specific Adverse Reactions R
Dronedaron
Adverse Reaction Dronedarone
Pulmonary toxicity 32/3,205 (1.0)
Thyroid toxicity 128/3,205 (4.0)
Hepatic toxicity 112/3,205 (3.5)
Symptomatic bradyarrhythmia 89/3,205 (2.8)
Increase in serum creatinine 128/3,205 (4.0)
Values are n/N (%). *Data are pooled from those studies in which the
of drug therapy.
NR  not reported.arone instead of amiodarone, there would be 228 more (ecurrences of AF at 1 year in exchange for 9.6 fewer deaths
nd 62 fewer adverse events requiring discontinuation of
rug.
Despite more limited efficacy for preventing AF, there
ppears to be a mortality benefit to avoiding toxicity in this
elect population. As in CAST (Cardiac Arrhythmia Sup-
ression Trial), complete arrhythmia suppression in all
atients may not translate into better survival, particularly
n the setting of poor ventricular function (2). The
NDROMEDA (Antiarrhythmic Trial with Dronedarone
n Moderate-to-Severe Congestive Heart Failure Evaluat-
ng Morbidity Decrease) trial was stopped early because of
n unfavorable rate of mortality in the dronedarone arm (28).
What would it take to definitively determine whether
ronedarone improves survival compared with amiodarone?
he overall death rate in the ATHENA trial was 5.5%
uring the course of 22 months. In a similar population, a
rial with 80% power (2-sided alpha 0.05) to detect a 20%
ortality decrease would require approximately 14,000 pa-
ients. Until direct comparisons with sufficient statistical
ower for these outcomes are available, indirect estimates
with their inherent limitations) may help quantify the
verall clinical benefit. Although indirect comparisons and
imited head-to-head data lack precision, definitive trials
ill be expensive. This dilemma illustrates the challenges
acing architects of comparative effectiveness policies.
tudy limitations. Our analysis was restricted to random-
zed controlled trials. Although randomized controlled trials
inimize bias, they may not reflect patients treated in
eneral clinical practice. Indirect meta-analysis allows esti-
ates of treatment effect that are less biased than pooled
vent rates. Even so, clinical differences can produce dispar-
ty among trials included in meta-analyses (29) and cause
iscrepancies between meta-analyses and subsequent large,
ontrolled trials. For example, the dronedarone trials included
n this meta-analysis excluded patients with permanent AF,
hich may have biased the results against amiodarone. This
nalysis included trials with an average follow-up of 1 year and
oes not address longer-term efficacy or safety. We did not
ave access to patient-level data and therefore relied on tabular
ublished data. The only available direct treatment comparison
ug Termination*ring Study Drug Termination*
lacebo Amiodarone vs. Placebo
Placebo Amiodarone Placebo
20/2,802 (0.7) 2/419 (0.5) 1/245 (0.4)
83/2,802 (3.0) 12/161 (7.5) 0/113 (0)
69/2,802 (2.5) 1/161 (0.1) 0/113 (0)
31/2,802 (1.1) 6/161 (3.7) 0/113 (0)
32/2,802 (1.1) NR NR
s reported organ-specific adverse reactions requiring discontinuationdy Drequi
e vs. P
authorthe DIONYSOS trial) has not yet completed the peer-review
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September 15, 2009:1089–95 Dronedarone and Amiodaronerocess. Finally, our analysis ignores nonfatal events, such as
troke, which may heavily influence clinical decision-making.
onclusions
everal phase 3 randomized controlled trials have compared
ronedarone with placebo. Indirect meta-analysis and direct
andomized data suggest that dronedarone has substantially
ess efficacy for the maintenance of sinus rhythm. However,
ronedarone therapy is associated with less adverse effects
nd treatment discontinuation and appears to decrease
ardiovascular events. More long-term data are needed to
efine these estimates and to define the optimum balance of
fficacy and toxicity for patients with AF.
eprint requests and correspondence: Dr. Jonathan P. Piccini,
uke Clinical Research Institute, Duke University Medical Center
31115, Durham, North Carolina 27710. E-mail: jonathan.
iccini@duke.edu.
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